$PLSE
Pulse Biosciences Inc

2021 Q1 Form 10-K Financial Statement

#000162510121000014 Filed on March 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 2019 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $500.0K
YoY Change -16.67%
Gross Profit -$500.0K
YoY Change -16.67%
Gross Profit Margin
Selling, General & Admin $8.960M $22.86M $7.170M
YoY Change 60.0% 2.37% 87.7%
% of Gross Profit
Research & Development $9.063M $26.44M $6.590M
YoY Change 46.63% 5.94% 29.72%
% of Gross Profit
Depreciation & Amortization $100.0K $400.0K $270.0K
YoY Change 0.0% -20.0% -22.86%
% of Gross Profit
Operating Expenses $18.53M $49.97M $13.93M
YoY Change 55.02% 4.19% 53.76%
Operating Profit -$18.53M -$49.97M -$13.79M
YoY Change 4.19% 54.0%
Interest Expense $114.0K $114.0K $140.0K
YoY Change 42.5% -88.4% 0.0%
% of Operating Profit
Other Income/Expense, Net -$114.0K $114.0K $0.00
YoY Change -88.4% -100.0%
Pretax Income -$18.64M -$49.85M -$13.79M
YoY Change 57.03% 6.13% 54.08%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$18.64M -$49.85M -$13.79M
YoY Change 57.0% 6.13% 54.0%
Net Earnings / Revenue
Basic Earnings Per Share -$2.14
Diluted Earnings Per Share -$715.0K -$2.144M -$663.0K
COMMON SHARES
Basic Shares Outstanding 26.09M 23.25M 20.79M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.88M $20.48M $25.40M
YoY Change 276.84% -19.37% -57.37%
Cash & Equivalents $59.88M $12.46M $6.899M
Short-Term Investments $0.00 $8.010M $18.50M
Other Short-Term Assets $960.0K $1.860M $1.010M
YoY Change 74.55% 84.16% 29.49%
Inventory $1.135M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $61.98M $22.34M $26.40M
YoY Change 277.19% -15.38% -56.26%
LONG-TERM ASSETS
Property, Plant & Equipment $2.430M $11.92M $2.566M
YoY Change -7.71% 55.21% 18.09%
Goodwill $2.791M $2.791M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $365.0K $370.0K $494.0K
YoY Change -35.05% -24.49% 389.11%
Total Long-Term Assets $18.58M $18.95M $15.51M
YoY Change 20.58% 22.1% 50.92%
TOTAL ASSETS
Total Short-Term Assets $61.98M $22.34M $26.40M
Total Long-Term Assets $18.58M $18.95M $15.51M
Total Assets $80.56M $41.29M $41.92M
YoY Change 153.0% -1.5% -40.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.164M $1.720M $1.963M
YoY Change 78.25% -12.24% 54.32%
Accrued Expenses $5.617M $5.870M $2.496M
YoY Change 171.22% 134.8% 75.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $120.0K
YoY Change
Total Short-Term Liabilities $8.528M $7.590M $4.459M
YoY Change 152.08% 70.18% 43.47%
LONG-TERM LIABILITIES
Long-Term Debt $41.00M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.63M $10.81M $6.720M
YoY Change 58.89% 60.86% 460.0%
Total Long-Term Liabilities $51.63M $10.81M $6.720M
YoY Change 671.75% 60.86% 460.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.528M $7.590M $4.459M
Total Long-Term Liabilities $51.63M $10.81M $6.720M
Total Liabilities $60.16M $18.40M $11.18M
YoY Change 497.24% 64.58% 159.59%
SHAREHOLDERS EQUITY
Retained Earnings -$191.2M -$122.7M
YoY Change 42.08% 62.03%
Common Stock $211.6M $153.4M
YoY Change 35.35% 8.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.40M $22.89M $30.74M
YoY Change
Total Liabilities & Shareholders Equity $80.56M $41.29M $41.92M
YoY Change 153.0% -1.5% -40.66%

Cashflow Statement

Concept 2021 Q1 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$18.64M -$49.85M -$13.79M
YoY Change 57.0% 6.13% 54.0%
Depreciation, Depletion And Amortization $100.0K $400.0K $270.0K
YoY Change 0.0% -20.0% -22.86%
Cash From Operating Activities -$11.69M -$35.37M -$9.200M
YoY Change 21.46% 3.45% 45.8%
INVESTING ACTIVITIES
Capital Expenditures $51.00K $441.0K $40.00K
YoY Change -70.18% -27.47% -200.0%
Acquisitions
YoY Change
Other Investing Activities $8.000M $10.49M $6.490M
YoY Change -23.74% -210.54% 3.84%
Cash From Investing Activities $7.949M $10.04M $6.530M
YoY Change -23.0% -199.44% 4.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.892M $29.43M
YoY Change 1818.43%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 51.16M 30.89M 0.000
YoY Change 19278.03% 37564.63% -100.0%
NET CHANGE
Cash From Operating Activities -11.69M -35.37M -9.200M
Cash From Investing Activities 7.949M 10.04M 6.530M
Cash From Financing Activities 51.16M 30.89M 0.000
Net Change In Cash 47.42M 5.564M -2.670M
YoY Change 4813.99% -112.59% -105.96%
FREE CASH FLOW
Cash From Operating Activities -$11.69M -$35.37M -$9.200M
Capital Expenditures $51.00K $441.0K $40.00K
Free Cash Flow -$11.74M -$35.81M -$9.240M
YoY Change 19.86% 2.91% 47.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001625101
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 plse Directors And Officers Liability Insurance Period
DirectorsAndOfficersLiabilityInsurancePeriod
P1Y
CY2020 plse Directors And Officers Liability Insurance Period
DirectorsAndOfficersLiabilityInsurancePeriod
P1Y
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2017Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018 us-gaap Revenues
Revenues
CY2019 us-gaap Revenues
Revenues
CY2020 us-gaap Revenues
Revenues
CY2020Q4 us-gaap Assets Current
AssetsCurrent
22339000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
26403000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2478000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-34899
CY2020 dei Entity Registrant Name
EntityRegistrantName
Pulse Biosciences, Inc.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5696597
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
3957 Point Eden Way
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
CY2020 dei City Area Code
CityAreaCode
510
CY2020 dei Local Phone Number
LocalPhoneNumber
906-4600
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2020 dei Trading Symbol
TradingSymbol
PLSE
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
135220301
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26086931
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12463000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6899000
CY2020Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
8012000
CY2019Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
18499000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1864000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1005000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2566000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3882000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4547000
CY2020Q4 us-gaap Goodwill
Goodwill
2791000
CY2019Q4 us-gaap Goodwill
Goodwill
2791000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9438000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5114000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
365000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
494000
CY2020Q4 us-gaap Assets
Assets
41293000
CY2019Q4 us-gaap Assets
Assets
41915000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1717000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1963000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5326000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2496000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
542000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7585000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4459000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10814000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6719000
CY2020Q4 us-gaap Liabilities
Liabilities
18399000
CY2019Q4 us-gaap Liabilities
Liabilities
11178000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25550000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25550000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20825000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20825000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
21000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
195410000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
153401000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172540000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122689000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22894000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
30737000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41293000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41915000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22856000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22327000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20045000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26444000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24961000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17253000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
665000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
666000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
665000
CY2020 us-gaap Operating Expenses
OperatingExpenses
49965000
CY2019 us-gaap Operating Expenses
OperatingExpenses
47954000
CY2018 us-gaap Operating Expenses
OperatingExpenses
37963000
CY2020 us-gaap Interest Income Operating
InterestIncomeOperating
114000
CY2019 us-gaap Interest Income Operating
InterestIncomeOperating
983000
CY2018 us-gaap Interest Income Operating
InterestIncomeOperating
446000
CY2018 us-gaap Other Noninterest Expense
OtherNoninterestExpense
28000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
114000
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
983000
CY2018 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
418000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-49851000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-46971000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-37545000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-49851000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-46971000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-37545000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49856000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46966000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37495000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.14
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.26
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.20
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23248000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20746000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17078000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
45995000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
498000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
327000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12338000
CY2018 plse Tax Payments Related To Shares Withheld For Vested Restricted Stock
TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStock
-115000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-37545000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
66334000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
272000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
423000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11287000
CY2019 plse Tax Payments Related To Shares Withheld For Vested Restricted Stock
TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStock
-613000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-46971000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
30737000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
887000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
490000
CY2020 plse Issuance Of Shares Upon Exercise Of Warrants
IssuanceOfSharesUponExerciseOfWarrants
1127000
CY2020 plse Stock Issued During Period Value Rights Offering
StockIssuedDuringPeriodValueRightsOffering
29434000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10075000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-49851000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22894000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-49851000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-46971000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-37545000
CY2020 us-gaap Depreciation
Depreciation
430000
CY2019 us-gaap Depreciation
Depreciation
494000
CY2018 us-gaap Depreciation
Depreciation
645000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-119000
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-28000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
665000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
666000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
665000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
10075000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
11287000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
12338000
CY2020 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-5000
CY2019 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
521000
CY2018 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
140000
CY2020 plse Gain Loss On Government Securities
GainLossOnGovernmentSecurities
8000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-194000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
226000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
367000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-266000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
646000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
490000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2830000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
841000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
387000
CY2020 plse Noncash Adjustment Right Of Use Assets
NoncashAdjustmentRightOfUseAssets
-509000
CY2019 plse Noncash Adjustment Right Of Use Assets
NoncashAdjustmentRightOfUseAssets
-68000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-129000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
393000
CY2020 plse Noncash Adjustment Lease Liabilities
NoncashAdjustmentLeaseLiabilities
-196000
CY2019 plse Noncash Adjustment Lease Liabilities
NoncashAdjustmentLeaseLiabilities
-76000
CY2018 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-397000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35365000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34185000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23896000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
441000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
608000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
276000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
29025000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
77993000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
40297000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
35000000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
68500000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
41815000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4510000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
24875000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10044000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10101000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26117000
CY2020 plse Proceeds From Exercises Of Stock Options And Warrants
ProceedsFromExercisesOfStockOptionsAndWarrants
961000
CY2019 plse Proceeds From Exercises Of Stock Options And Warrants
ProceedsFromExercisesOfStockOptionsAndWarrants
272000
CY2018 plse Proceeds From Exercises Of Stock Options And Warrants
ProceedsFromExercisesOfStockOptionsAndWarrants
498000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
490000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
423000
CY2018 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
327000
CY2020 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
29434000
CY2018 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
44786000
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
613000
CY2020Q4 plse Fair Value Equity Level12 And3 Transfers Amount
FairValueEquityLevel12And3TransfersAmount
0
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
24928000
CY2019 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
CY2020 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
CY2019Q4 plse Fair Value Equity Level12 And3 Transfers Amount
FairValueEquityLevel12And3TransfersAmount
0
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
115000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30885000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
82000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45496000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5564000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-44204000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
47717000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6899000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51103000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3386000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12463000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6899000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51103000
CY2020 plse Other Receivable From Exercise Of Warrants And Stock Options
OtherReceivableFromExerciseOfWarrantsAndStockOptions
1053000
CY2020 us-gaap Available For Sale Securities Transfers To Trading Gains Losses Net
AvailableForSaleSecuritiesTransfersToTradingGainsLossesNet
-5000
CY2019 us-gaap Available For Sale Securities Transfers To Trading Gains Losses Net
AvailableForSaleSecuritiesTransfersToTradingGainsLossesNet
5000
CY2018 us-gaap Available For Sale Securities Transfers To Trading Gains Losses Net
AvailableForSaleSecuritiesTransfersToTradingGainsLossesNet
50000
CY2020 us-gaap Contribution Of Property
ContributionOfProperty
20000
CY2019 us-gaap Contribution Of Property
ContributionOfProperty
279000
CY2018 us-gaap Contribution Of Property
ContributionOfProperty
33000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Estimates include, but are not limited to, the valuation of investments, clinical trial accruals, the valuation and recognition of stock-based compensation and useful lives assigned to long-lived assets. Actual amounts could differ from these estimates</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Concentration </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">of</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> Credit Risk</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; color: #333333;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and investments. The Company places its cash equivalents and investments with high credit quality financial institutions and, by policy, limits the amounts invested with any one financial institution or issuer. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses since inception. </span></p>
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5762809
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4139639
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3392778
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
500000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
600000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
600000
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
0
CY2020Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
0
CY2020Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
8013000
CY2020Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
8012000
CY2019Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
18495000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2019Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
18499000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
8012000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
18499000
CY2020Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
8012000
CY2019Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
18499000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
17192000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.19
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.18
CY2019 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1973810
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4394000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4052000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1916000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1486000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2478000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2566000
CY2017Q3 plse Tenant Improvement Allowance Capitalized
TenantImprovementAllowanceCapitalized
2100000
CY2020 us-gaap Depreciation
Depreciation
400000
CY2019 us-gaap Depreciation
Depreciation
500000
CY2018 us-gaap Depreciation
Depreciation
600000
CY2020 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P12Y
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7985000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7985000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4103000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3438000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3882000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4547000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
665000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
665000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
665000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
665000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
665000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
557000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3882000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3324000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1699000
CY2020Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1563000
CY2020Q4 plse Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
188000
CY2019Q4 plse Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
262000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
87000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
51000
CY2019Q4 plse Accrued Property And Equipment
AccruedPropertyAndEquipment
234000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
164000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
250000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5326000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2496000
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3749186
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
175066
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.07
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
351234
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.71
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
157502
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
23.64
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5039194
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.26
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y9M29D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2552230
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
17.03
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1600000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000.0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1800000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6700000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
8400000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6400000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10075000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11287000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12338000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9600000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-37545000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-49851000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-46971000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-37545000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
3000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
3000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-49851000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-46971000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
3000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3000
CY2020 plse Income Tax Expense Benefit Component Of Operating Expense
IncomeTaxExpenseBenefitComponentOfOperatingExpense
3000
CY2019 plse Income Tax Expense Benefit Component Of Operating Expense
IncomeTaxExpenseBenefitComponentOfOperatingExpense
3000
CY2018 plse Income Tax Expense Benefit Component Of Operating Expense
IncomeTaxExpenseBenefitComponentOfOperatingExpense
3000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.084
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.050
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.070
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.021
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.020
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.020
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.433
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.180
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.280
CY2020 plse Effective Income Tax Rate Reconciliation Deferred Adjustment Percent
EffectiveIncomeTaxRateReconciliationDeferredAdjustmentPercent
0.085
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.042
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Transition Tax On Accumulated Foreign Earnings Percent
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTaxOnAccumulatedForeignEarningsPercent
2.0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008
CY2020Q4 plse Deferred Tax Assets Accruals
DeferredTaxAssetsAccruals
894000
CY2019Q4 plse Deferred Tax Assets Accruals
DeferredTaxAssetsAccruals
119000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
36531000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20755000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
5431000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4409000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9391000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5473000
CY2020Q4 plse Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
3339000
CY2019Q4 plse Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
1411000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
55586000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32167000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51973000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30369000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3613000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1798000
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
486000
CY2019Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
434000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1500000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
900000
CY2020Q4 plse Deferred Tax Liability Right Of Use Assets
DeferredTaxLiabilityRightOfUseAssets
3096000
CY2019Q4 plse Deferred Tax Liability Right Of Use Assets
DeferredTaxLiabilityRightOfUseAssets
1364000
CY2020Q4 us-gaap Deferred Tax Liabilities Other Finite Lived Assets
DeferredTaxLiabilitiesOtherFiniteLivedAssets
31000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3613000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1798000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2500000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1470000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
877000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
512000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1021000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
593000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
365000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2491000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1470000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
877000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
21600000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7700000
CY2020Q4 us-gaap Security Deposit Liability
SecurityDepositLiability
30000000
CY2017Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
15700
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1643000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1806000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1845000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1910000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
10214000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17418000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6062000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11356000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1045000
CY2020 plse Operating Lease Liabilities Arising From Rou Assets Including Impact Of Adopting Asc842
OperatingLeaseLiabilitiesArisingFromRouAssetsIncludingImpactOfAdoptingAsc842
4833000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
542000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10814000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11356000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y9M29D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2018 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0
CY2019 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0
CY2020 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0

Files In Submission

Name View Source Status
0001625101-21-000014-index-headers.html Edgar Link pending
0001625101-21-000014-index.html Edgar Link pending
0001625101-21-000014.txt Edgar Link pending
0001625101-21-000014-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plse-20201231.xsd Edgar Link pending
plse-20201231x10k.htm Edgar Link pending
plse-20201231x10kg001.jpg Edgar Link pending
plse-20201231x10k_htm.xml Edgar Link completed
plse-20201231xex10_10.htm Edgar Link pending
plse-20201231xex10_10g001.jpg Edgar Link pending
plse-20201231xex10_10g002.jpg Edgar Link pending
plse-20201231xex21_1.htm Edgar Link pending
plse-20201231xex23_1.htm Edgar Link pending
plse-20201231xex31_1.htm Edgar Link pending
plse-20201231xex31_2.htm Edgar Link pending
plse-20201231xex32_1.htm Edgar Link pending
plse-20201231_cal.xml Edgar Link unprocessable
plse-20201231_def.xml Edgar Link unprocessable
plse-20201231_lab.xml Edgar Link unprocessable
plse-20201231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending